Managing Vision Care During Systemic Treatment

Abstract

Systemic therapies, including chemotherapeutics, immunomodulators, and biologics, have revolutionized the management of various systemic diseases but are frequently associated with ophthalmic side effects. This review provides a comprehensive, evidence-based synthesis of the epidemiology, pathophysiology, risk factors, clinical features, diagnosis, and management of vision-related complications arising during systemic treatment. It highlights recent advances, emerging therapies, and current guideline recommendations, offering practical insights for medical professionals to optimize vision care and minimize morbidity in patients receiving systemic therapies.

Introduction

With the expanding indications for systemic therapies in oncology, rheumatology, infectious diseases, and other medical specialties, the incidence of vision-threatening adverse events has become increasingly relevant. Ocular complications may impact quality of life, treatment adherence, and clinical outcomes. Early recognition and interdisciplinary collaboration are essential to mitigate risks and ensure optimal patient care. This article critically appraises the current literature on vision care during systemic treatment, emphasizing the importance of proactive ophthalmic surveillance and tailored management strategies.

Epidemiology / Disease Burden

Ocular toxicities are reported in up to 20-30% of patients receiving systemic therapies, with incidence varying by drug class and patient comorbidities. Cytotoxic chemotherapeutics, such as cytarabine and methotrexate, are associated with conjunctivitis and keratitis, while targeted agents and immune checkpoint inhibitors may cause uveitis, retinopathy, and optic neuropathy. In populations with hematologic malignancies or autoimmune diseases, the risk of vision loss is further compounded by disease-related ocular involvement. The burden of vision impairment is significant, affecting daily functioning, independence, and mental health.

Pathophysiology

The mechanisms underlying ocular adverse effects from systemic treatments are diverse and multifactorial. Many agents disrupt the blood-ocular barrier, leading to inflammatory or ischemic processes. For example, alkylating agents may induce microvascular injury and retinal ischemia, whereas immune checkpoint inhibitors unleash T-cell–mediated autoimmunity, resulting in uveitis or optic neuritis. Monoclonal antibodies may cross-react with ocular antigens, and corticosteroids, although protective, can increase intraocular pressure and cataract formation. The interplay between systemic inflammation, direct cytotoxicity, and immune dysregulation underscores the need for individualized risk assessment.

Risk Factors

Several factors predispose patients to ocular complications during systemic treatment. Pre-existing ophthalmic disease, advanced age, diabetes, hypertension, and genetic polymorphisms affecting drug metabolism heighten vulnerability. High cumulative drug doses, rapid dose escalation, and concomitant use of multiple agents further amplify risk. Patients with compromised renal or hepatic function may experience increased drug exposure, exacerbating toxicity. Recognizing these risk factors facilitates targeted surveillance and early intervention.

Clinical Features

Ophthalmic complications present with a spectrum of symptoms, ranging from mild discomfort to profound vision loss. Common manifestations include dry eye, photophobia, blurred vision, floaters, pain, and visual field defects. Specific findings are drug-dependent: cytarabine-induced keratoconjunctivitis, hydroxychloroquine maculopathy, interferon-associated retinopathy, and checkpoint inhibitor-related uveitis or optic neuritis. Prompt recognition of red-flag symptoms such as sudden vision loss, severe pain, or new-onset diplopia is essential for timely referral and management.

Diagnosis

Diagnosis of ocular toxicity relies on detailed patient history, comprehensive ophthalmologic examination, and adjunctive investigations. Baseline assessment before initiation of systemic therapy is recommended for high-risk drugs. Slit-lamp biomicroscopy, dilated fundus examination, optical coherence tomography (OCT), and fundus fluorescein angiography are invaluable for characterizing structural and microvascular changes. Visual field testing and electrophysiological studies may be warranted in cases of suspected optic neuropathy. Multidisciplinary communication between treating physicians and ophthalmologists ensures accurate attribution of findings and guides management decisions.

Treatment & Management

Optimal management entails a balance between systemic disease control and ocular safety. For mild ophthalmic adverse effects, supportive measures such as lubricants, topical steroids, or antihistamines may suffice. Moderate-to-severe cases often necessitate dose adjustment, temporary discontinuation, or substitution of the offending agent. Immunosuppressive or immunomodulatory therapy may be indicated for immune-mediated complications. Early intervention with corticosteroids, either systemic or local, can preserve vision in cases of uveitis or optic neuritis. Patient education regarding symptom vigilance and prompt reporting is crucial for minimizing irreversible damage.

Recent Advances / Emerging Therapies

Recent research highlights the role of precision medicine and pharmacogenomics in predicting and mitigating ocular toxicity. Biomarkers such as HLA genotypes and serum cytokine profiles may stratify risk, enabling preemptive monitoring. Novel agents with improved safety profiles are under investigation, including next-generation kinase inhibitors and monoclonal antibodies with reduced ocular penetration. Advances in imaging, such as ultra-widefield OCT and adaptive optics, facilitate early detection of subclinical changes. Digital health platforms and teleophthalmology are emerging as tools for remote screening and monitoring, particularly in resource-limited settings.

Guideline Recommendations

Professional societies, including the American Academy of Ophthalmology and the American Society of Clinical Oncology, recommend baseline and periodic ophthalmic evaluations for patients on high-risk systemic therapies. Individualized surveillance schedules are based on drug class, risk factors, and duration of therapy. Interdisciplinary care pathways, integrating oncologists, rheumatologists, and ophthalmologists, are advocated to streamline diagnosis and management. Patient education materials and decision aids support shared decision-making and enhance adherence to monitoring protocols.

Conclusion

Vision care during systemic treatment is a critical component of comprehensive patient management. Awareness of the epidemiology, mechanisms, and clinical manifestations of ocular toxicity, coupled with evidence-based diagnostic and management strategies, can significantly reduce the burden of vision impairment. Ongoing research into pharmacogenomics and digital health promises further improvements in early detection and individualized risk mitigation. Interdisciplinary collaboration and adherence to guideline-based care are essential to safeguard visual outcomes and optimize quality of life for patients receiving systemic therapies.